ECSP11011021A - Antagonistas de la via hedgehog de ftalazina disustituida - Google Patents

Antagonistas de la via hedgehog de ftalazina disustituida

Info

Publication number
ECSP11011021A
ECSP11011021A EC2011011021A ECSP11011021A ECSP11011021A EC SP11011021 A ECSP11011021 A EC SP11011021A EC 2011011021 A EC2011011021 A EC 2011011021A EC SP11011021 A ECSP11011021 A EC SP11011021A EC SP11011021 A ECSP11011021 A EC SP11011021A
Authority
EC
Ecuador
Prior art keywords
ftalazina
disustituida
antagonists
hedgehog
via hedgehog
Prior art date
Application number
EC2011011021A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Jolie Anne Bastian
Daniel Jhon Sall
Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41566219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011021(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP11011021A publication Critical patent/ECSP11011021A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención provee antagonistas de la vía hedgehog de ftalizina 1,4-disustituida novedosos útiles en el tratamiento de cáncer.
EC2011011021A 2008-11-03 2011-05-02 Antagonistas de la via hedgehog de ftalazina disustituida ECSP11011021A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11070308P 2008-11-03 2008-11-03

Publications (1)

Publication Number Publication Date
ECSP11011021A true ECSP11011021A (es) 2011-06-30

Family

ID=41566219

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011021A ECSP11011021A (es) 2008-11-03 2011-05-02 Antagonistas de la via hedgehog de ftalazina disustituida

Country Status (30)

Country Link
US (1) US8404687B2 (es)
EP (1) EP2364185B1 (es)
JP (1) JP2012507535A (es)
KR (1) KR101335746B1 (es)
CN (1) CN102202737B (es)
AU (1) AU2009320251C1 (es)
BR (1) BRPI0921437A2 (es)
CA (1) CA2742539C (es)
CL (1) CL2011000979A1 (es)
CO (1) CO6382123A2 (es)
CR (1) CR20110202A (es)
CY (1) CY1114023T1 (es)
DK (1) DK2364185T3 (es)
EA (1) EA018931B1 (es)
EC (1) ECSP11011021A (es)
ES (1) ES2418479T3 (es)
HK (1) HK1159010A1 (es)
HR (1) HRP20130527T1 (es)
IL (1) IL211841A0 (es)
MA (1) MA32726B1 (es)
MX (1) MX2011004683A (es)
NZ (1) NZ591945A (es)
PE (1) PE20110433A1 (es)
PL (1) PL2364185T3 (es)
PT (1) PT2364185E (es)
SI (1) SI2364185T1 (es)
TN (1) TN2011000166A1 (es)
UA (1) UA102115C2 (es)
WO (1) WO2010062507A1 (es)
ZA (1) ZA201102448B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065718A1 (es) * 2007-03-15 2009-06-24 Novartis Ag Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos.
EA201071248A1 (ru) 2008-04-29 2011-06-30 Эли Лилли Энд Компани Дизамещенные фталазиновые антагонисты пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
BRPI0921777A2 (pt) 2008-11-17 2016-01-12 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
WO2024064245A1 (en) * 2022-09-23 2024-03-28 Merck Sharp & Dohme Llc Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
IL124461A (en) 1996-01-15 2000-07-26 Janssen Pharmaceutica Nv Angiogenesis inhibiting 3-(1,2,4-thiadiazol-5-yl)piperazine pyridazine derivatives their preparation and pharmaceutical compositions containing them
KR100622323B1 (ko) * 1996-10-01 2006-11-30 교와 핫꼬 고교 가부시끼가이샤 질소-함유헤테로고리화합물
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP2003501395A (ja) 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) * 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
CN1984904A (zh) 2004-05-08 2007-06-20 神经能质公司 3－芳基－5,6－二取代哒嗪
JP5143558B2 (ja) * 2004-09-02 2013-02-13 ジェネンテック，インコーポレイティド ヘッジホッグシグナル伝達のピリジルインヒビター
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
AR065718A1 (es) * 2007-03-15 2009-06-24 Novartis Ag Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos.
CA2690378A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009035568A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
EA201071248A1 (ru) 2008-04-29 2011-06-30 Эли Лилли Энд Компани Дизамещенные фталазиновые антагонисты пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2743483C (en) 2008-11-17 2014-03-11 Eli Lilly And Company Tetrasubstituted pyridazine hedgehog pathway antagonists
BRPI0921777A2 (pt) 2008-11-17 2016-01-12 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
HK1159010A1 (en) 2012-07-27
EA018931B1 (ru) 2013-11-29
CY1114023T1 (el) 2016-07-27
EA201170640A1 (ru) 2011-12-30
MA32726B1 (fr) 2011-10-02
PE20110433A1 (es) 2011-07-09
PL2364185T3 (pl) 2013-10-31
UA102115C2 (ru) 2013-06-10
SI2364185T1 (sl) 2013-07-31
KR101335746B1 (ko) 2013-12-12
US20110190304A1 (en) 2011-08-04
CO6382123A2 (es) 2012-02-15
EP2364185B1 (en) 2013-05-22
US8404687B2 (en) 2013-03-26
CN102202737B (zh) 2014-03-26
JP2012507535A (ja) 2012-03-29
BRPI0921437A2 (pt) 2018-10-30
CA2742539A1 (en) 2010-06-03
CL2011000979A1 (es) 2011-10-07
IL211841A0 (en) 2011-06-30
CR20110202A (es) 2011-06-09
TN2011000166A1 (en) 2012-12-17
AU2009320251A1 (en) 2010-06-03
MX2011004683A (es) 2011-06-20
WO2010062507A1 (en) 2010-06-03
ZA201102448B (en) 2012-09-26
CN102202737A (zh) 2011-09-28
AU2009320251B2 (en) 2013-01-24
HRP20130527T1 (en) 2013-07-31
EP2364185A1 (en) 2011-09-14
DK2364185T3 (da) 2013-06-03
ES2418479T3 (es) 2013-08-14
PT2364185E (pt) 2013-07-24
CA2742539C (en) 2014-05-06
NZ591945A (en) 2012-10-26
KR20110066212A (ko) 2011-06-16
AU2009320251C1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR11741A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
HN2011002809A (es) Compuestos de vinil indazolilo
MY153915A (en) Organic compounds
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
EA201170700A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
TN2010000489A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
CY1114078T1 (el) Ανταγωνιστες διυποκατεστημενης φθαλαζινης του μονοπατιου hedgehog
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
CL2008000256S1 (es) Perfil.
CL2008000258S1 (es) Perfil.
CL2008000260S1 (es) Perfil.
CL2008000262S1 (es) Perfil.
CL2008000265S1 (es) Perfil.
CL2008000267S1 (es) Perfil.